Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ultragenyx Pharmaceutical

Request full access

Treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases

Novato, United StatesFounded 2010Biotech & Life Sciences
Valuation $1.81B Market cap · Aug/2026
Revenue $748M Latest reported FY

At a glance

Status
Listed
Founded
2010
Headquarters
Novato, United States
Listing
IPO 2014
Sector
Biotech & Life Sciences
Outcome tier
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafias, market maps, lists and research connected to this company by Dealroom
Market maps in Biotech & Life Sciences
Market map Rare Disease Therapeutics & Technologies Landscape Market map 1k+ Global Genetics & Genomics startups Market map Companies building biology-native data infrastructure Apr 30, 2026
Unicorn lists
Biotech & Life Sciences unicorns Unicorn list Biotech & Life Sciences unicorns Unicorns in United States Unicorn list Unicorns in United States

News

News FDA approves Ultragenyx's FAYUVI, first-ever treatment for Sanfilippo syndrome type A Sep 18, 2026 News Ultragenyx's Angelman syndrome drug fails pivotal Phase 3 trial Sep 3, 2026 News Ultragenyx lands FDA approval for GENGLYCOS, first gene therapy for glycogen storage disease type Ia Aug 20, 2026

Open roles

Track hiring at Ultragenyx PharmaceuticalOpen roles, team growth and hiring by functionBook a demo
Looking for a job? The startup jobs board lists open roles.Startups hiring now →

Ultragenyx Pharmaceutical in the Novato ecosystem

Live from Dealroom

The Ultragenyx Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Takeda Ventures
  • TPG

Series B and later5 investors entered at this stage

Talent

Book a demo to see the people
Employees mapped 1,531 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 26 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
21 countries with
team presence
🇺🇸 United States83.2%
🇧🇷 Brazil3.9%
🇨🇭 Switzerland2.6%
🇲🇽 Mexico1.5%
🇦🇷 Argentina1.4%
Top 5 of 21 shown
Web traffic by country
24K monthly visits
across markets
🇺🇸 United States56.7%
🇮🇳 India12.5%
🇯🇵 Japan8.3%
🇲🇽 Mexico7.1%
🇬🇧 United Kingdom3.8%
Top 5 markets shown

Patents

Estimated portfolio value
$86M

50 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Ultragenyx Pharmaceutical was the backer or acquirer, 2017–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Ultragenyx Pharmaceutical's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Ultragenyx Pharmaceutical's portfolio, mapped.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Ultragenyx Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Ultragenyx Pharmaceutical on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles